T2 Biosystems (TTOO) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Market need and clinical impact

• Sepsis is the leading cause of death and hospitalization costs in US hospitals, with 350,000 deaths and $62 billion in annual costs.

• Current standard of care is failing, with high rates of rehospitalization among sepsis survivors.

• Rapid, targeted antimicrobial therapy is critical, as each hour of delay increases mortality risk by up to 8%.

Technology differentiation and competitive landscape

• Magnetic resonance technology enables direct detection of pathogens in blood, bypassing the need for positive blood cultures.

• Competitors require positive blood cultures, which can delay diagnosis and miss cases due to poor sensitivity.

• Blood culture supply shortages highlight the need for culture-independent diagnostics.

Commercialization, global expansion, and partnerships

• Installed base is about 200 instruments, split between US and international markets, with significant runway for growth.

• Distribution network covers 45 countries, with major partners in Europe and expansion in Asia-Pacific, Middle East, and Latin America.

• Asia-Pacific, especially China and India, represents a large, under-penetrated market, with plans to partner locally.

• Negotiations are underway with a major US healthcare company for commercial partnership, expected to close in Q3 2024.